News

Pfizer, BioNTech and COVID-19

Pfizer/BioNTech, Moderna win EU backing for updated COVID shots
An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorizations for COVID-19 shots developed by Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) targeting the LP.
Pfizer and BioNTech Receive Positive EMA Backing for Updated COVID Vaccine
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) have gained a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for their updated monovalent COVID-19 vaccine targeting the LP.
Pfizer, BioNTech Get CHMP Backing for Updated Covid-19 Vaccine
New York drugmaker Pfizer and Mainz, Germany, immunotherapy company BioNTech said the European Commission, which generally follows CHMP's advice, will now review the recommendation, with a final decision expected soon. The companies added that the updated vaccine will be ready to ship immediately upon approval.
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 202
EU regulator backs Moderna's updated COVID vaccine
The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the vaccine maker said on Friday. The updated shot targets the LP.8.1 variant,
Fierce Biotech9d
BioNTech's chief strategy officer Ryan Richardson heads for the exit
BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...
BioNTech: More Uncertainty Emerges
BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...
USA Today4y
COVID vaccine: How BioNTech used cancer mRNA tech for coronavirus
When Özlem Türeci, co-founder of BioNTech, first heard about the novel coronavirus, she knew her company would have to work on a vaccine to fight it. American Amanda Anisimova upsets No. 1 Aryna ...
ABC News4y
Pfizer, BioNTech submit emergency authorization request to FDA Friday ...
Pfizer and partner BioNTech announced they have submitted a request on Friday to the U.S. Food and Drug Administration for emergency use authorization of their COVID-19 vaccine candidate.
Reuters3y
BioNTech CEO says vaccine upgrade on the cards, ready to move quickly
BioNTech should be able to adapt its coronavirus vaccine relatively quickly in response to the Omicron variant, and the next few weeks will show how urgently an upgrade is needed, its CEO Ugur ...
The Washington Post5y
Pfizer, BioNTech make $1.95 billion covid-19 vaccine deal with U.S ...
Pfizer, BioNTech reach $1.95 billion covid-19 vaccine deal with U.S. government. The contract is the largest yet under the Trump administration’s Operation Warp Speed program, and will start ...
Zacks Investment Research on MSN2d
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. BioNTech SE Sponsored ADR (BNTX) is a stock that can certainly grab the attention of ...
Reuters3y
BioNTech CEO says vaccine likely to protect against severe COVID from ...
BioNTech and Pfizer's COVID-19 vaccine will likely offer strong protection against any severe disease from the new Omicron virus variant, BioNTech's Chief Executive told Reuters, as the firm ...